Bill Sutherland: Right. And as you kind of hear about what’s going on in the industry with the NSA negotiations at the federal level, do you sense that after this huge delay that the cases are going to start, the filed cases are going to start to move through and be adjudicated?
John Farlinger: We hope so. We’ve talked to the CEOs of most of our competitors, at least the larger competitors over the last month. We’re all feeling the same frustration. I think we’ve been filibustered at the – really the rolling out of this No Surprises Act and almost no claims paid to anybody. Anecdotally, our team has been working really hard on the RCM side to get claims pushed through. We did get our first claim paid. Results were very optimistic, but it’s anecdotal information. We don’t have enough data yet. At a State level, we’re pretty sure what we’re going to get. And it’s almost working like clockwork now in the States where we are arbitrating, but Bill, it’s not – there isn’t a certainty to that. The other thing I will say is, the financial statements don’t reflect any upside from all these claims that are in queue to be arbitrated.
And we believe there is some upside there and there will be increased upside as this process starts, at least as it starts as it’s intended to be used going forward. So, there is some upside there. I think the feeling from the competitors that have been at this for 20 years is, this is probably the toughest they’ve seen it right now in that period, but most are optimistic that things are going to turn as the year goes on.
Bill Sutherland: Right. And then last one, now that you’ve gotten your cost on a per-patient basis down to $1,100, given the reimbursement mix that you’re looking at, I mean, is that a decent margin at this point?
John Farlinger: We want to go lower. We’re going to strive to get this closer to $1,000. That’s our goal in the first six months of this year. Won’t be easy, but at those numbers, I think we’ll be feeling much better about the business, and we’ve taken a number of steps in the first quarter to reduce the cost of delivery. And even looked at the financials from €˜21 to €˜22, you can see our cost of delivery and then our cost of goods basis has reduced. Certainly, we’ve made some good progress on the remote neurology side in getting additional margin there. We’ll pick up additional margin by getting out of the MSA business, and it’s going to be several hundred thousand dollars a month in margin that we will pick up going into Q2. I think those headwinds are going to work well for us, but the focus has got to be to continue to drive and run leaner going forward.
Bill Sutherland: Yes. Okay. Thanks for all the color, guys. Appreciate it.
Operator: Thank you. There were no other questions in queue at this time. I would now like to hand the call back to the Assure management team for closing remarks.
John Farlinger: Thanks. John Farlinger. Obviously, myself and the team are disappointed with certainly the reserves and the challenges of the interoperative neuromonitoring industry. At the same time, there are some tremendous data points that show that we are making significant improvement in our business, among those, making a significant dent in reducing the days to collect, making improvement in our cashflow, improving our corporate cash flow by almost 50% over the prior year, and total cash collections continuing to improve significantly. I think we’re going to very tightly monitor the accruals going forward. We did last year. We just did not have – I don’t think many people have visibility into the change in the arbitration rates that are going to happen at the end of the year, nor the rapid reduction in reimbursement as we saw it from €˜21 to €˜22.
